Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

Abstract Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype vectors contained no additional attenuating mutations in the rVSV genome. Here we describe rVSV vectors containing a full complement of VSV genes and expressing the Ebola virus (EBOV) GP from an additional transcription unit. These rVSV vectors contain the same combination of attenuating mutations used previously in the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), which expresses membrane-anchored EBOV GP from the first position in the genome (GP1), elicited a balanced cellular and humoral GP-specific immune response in mice. Guinea pigs immunized with a single dose of this vector were protected from any signs of disease following lethal EBOV challenge, while control animals died in 7–9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose protection of 2 macaques following lethal EBOV challenge. A single sham-vaccinated macaque died from disease due to EBOV infection. These results demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide safer alternatives to current EBOV vaccines.

[1]  H. Feldmann.  Ebola--a growing threat? , 2014, The New England journal of medicine.

[2]  W John Edmunds,et al.  Case fatality rate for Ebola virus disease in west Africa , 2014, The Lancet.

[3]  R. Price,et al.  Neurovirulence and Immunogenicity of Attenuated Recombinant Vesicular Stomatitis Viruses in Nonhuman Primates , 2014, Journal of Virology.

[4]  A. Takada,et al.  Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever , 2012, PloS one.

[5]  X. Qiu,et al.  Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection , 2012, PLoS neglected tropical diseases.

[6]  N. Mulherkar,et al.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. , 2011, The Journal of infectious diseases.

[7]  H. Feldmann,et al.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. , 2011, The Journal of infectious diseases.

[8]  J. Strong,et al.  Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. , 2011, The Journal of infectious diseases.

[9]  H. Ebihara,et al.  Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. , 2011, The Journal of infectious diseases.

[10]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[11]  A. MacNeil,et al.  Serologic Cross-Reactivity of Human IgM and IgG Antibodies to Five Species of Ebola Virus , 2011, PLoS neglected tropical diseases.

[12]  H. Feldmann,et al.  Progress in filovirus vaccine development: evaluating the potential for clinical use , 2011, Expert review of vaccines.

[13]  Pradeep Kota,et al.  Automated minimization of steric clashes in protein structures , 2011, Proteins.

[14]  V. Volchkov,et al.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations , 2010, Archives of Virology.

[15]  Kimihito Ito,et al.  Enzyme-Linked Immunosorbent Assay for Detection of Filovirus Species-Specific Antibodies , 2010, Clinical and Vaccine Immunology.

[16]  D. Cooper,et al.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation , 2009, Vaccine.

[17]  Steven J M Jones,et al.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. , 2008, Vaccine.

[18]  Larry R. Smith,et al.  Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses. , 2008, Vaccine.

[19]  D. Burton,et al.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor , 2008, Nature.

[20]  J. Gonzalez,et al.  Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. , 2007, The Journal of infectious diseases.

[21]  R. M. Hendry,et al.  Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice , 2007, Journal of Virology.

[22]  R. M. Hendry,et al.  Synergistic Attenuation of Vesicular Stomatitis Virus by Combination of Specific G Gene Truncations and N Gene Translocations , 2006, Journal of Virology.

[23]  W. Dowling,et al.  Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines , 2006, Journal of Virology.

[24]  H. Schnittler,et al.  Structure‐Function Analysis of the Soluble Glycoprotein, sGP, of Ebola Virus , 2006, Chembiochem : a European journal of chemical biology.

[25]  R. M. Hendry,et al.  An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. , 2006, Journal of virological methods.

[26]  J. Gonzalez,et al.  Fruit bats as reservoirs of Ebola virus , 2005, Nature.

[27]  C. Pallier.  [Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses]. , 2005, Virologie.

[28]  K. Subbarao,et al.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.

[29]  N. Sullivan,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[30]  K. Conzelmann.  Transcriptional Activation of Alpha/Beta Interferon Genes: Interference by Nonsegmented Negative-Strand RNA Viruses , 2005, Journal of Virology.

[31]  M. Mohamadzadeh,et al.  Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Roberts,et al.  Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge , 2001, Journal of Virology.

[33]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[34]  L. A. Ball,et al.  Moving the Glycoprotein Gene of Vesicular Stomatitis Virus to Promoter-Proximal Positions Accelerates and Enhances the Protective Immune Response , 2000, Journal of Virology.

[35]  L. A. Ball,et al.  Phenotypic Consequences of Rearranging the P, M, and G Genes of Vesicular Stomatitis Virus , 1999, Journal of Virology.

[36]  A. Roberts,et al.  Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors , 1999, Journal of Virology.

[37]  P. Jahrling,et al.  Pathogenesis of experimental Ebola virus infection in guinea pigs. , 1999, The Journal of infectious diseases.

[38]  P. Bates,et al.  Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines , 1998, Journal of Virology.

[39]  A. Sanchez,et al.  Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. , 1998, Science.

[40]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[41]  R. Zinkernagel,et al.  Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors , 1995, Journal of virology.

[42]  M. Whitt,et al.  Recombinant vesicular stomatitis viruses from DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Tesh,et al.  Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia. , 1987, The American journal of tropical medicine and hygiene.

[44]  A. Banerjee,et al.  Sequential transcription of the genes of vesicular stomatitis virus. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. A. Ball,et al.  Order of transcription of genes of vesicular stomatitis virus. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Tesh,et al.  Vesicular Stomatitis Virus (Indiana Serotype): Transovarial Transmission by Phlebotomine Sandflies , 1972, Science.

[47]  R. Tesh,et al.  Vesicular stomatitis virus, Indiana serotype: multiplication in and transmission by experimentally infected phlebotomine sandflies (Lutzomyia trapidoi). , 1971, American journal of epidemiology.

[48]  A. Jonkers.  The epizootiology of the vesicular stomatitis viruses: a reappraisal. , 1967, American journal of epidemiology.

[49]  K. Johnson,et al.  Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). , 1966, The American journal of tropical medicine and hygiene.

[50]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[51]  W. Dowling,et al.  Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines (cid:1) , 2007 .

[52]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.

[53]  C. Mandl,et al.  Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. , 1995, Vaccine.